Back to Search Start Over

MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae

Authors :
Instituto de Salud Carlos III
Ministerio de Economía y Competitividad (España)
European Commission
Red Española de Investigación en Patología Infecciosa
Delgado-Valverde, Mercedes
Valiente-Méndez, Adoración
Torres, Eva
Almirante, Benito
Gómez-Zorrilla, Silvia
Borrell, Núria
Aller-García, Ana Isabel
Gurguí, Mercè
Almela, Manel
Sanz, Mercedes
Bou, Germán
Martínez-Martínez, Luis
Cantón, Rafael
Lepe, José A.
Causse, Manuel
Gutiérrez-Gutiérrez, Belén
Pascual, Álvaro
Rodríguez-Baño, Jesús
Instituto de Salud Carlos III
Ministerio de Economía y Competitividad (España)
European Commission
Red Española de Investigación en Patología Infecciosa
Delgado-Valverde, Mercedes
Valiente-Méndez, Adoración
Torres, Eva
Almirante, Benito
Gómez-Zorrilla, Silvia
Borrell, Núria
Aller-García, Ana Isabel
Gurguí, Mercè
Almela, Manel
Sanz, Mercedes
Bou, Germán
Martínez-Martínez, Luis
Cantón, Rafael
Lepe, José A.
Causse, Manuel
Gutiérrez-Gutiérrez, Belén
Pascual, Álvaro
Rodríguez-Baño, Jesús
Publication Year :
2017

Abstract

[Objectives] To compare results of amoxicillin/clavulanate susceptibility testing using CLSI and EUCAST methodologies and to evaluate their impact on outcome in patients with bacteraemia caused by Enterobacteriaceae.<br />[Patients and methods] A prospective observational cohort study was conducted in 13 Spanish hospitals. Patients with bacteraemia due to Enterobacteriaceae who received empirical intravenous amoxicillin/clavulanate treatment for at least 48 h were included. MICs were determined following CLSI and EUCAST recommendations. Outcome variables were: failure at the end of treatment with amoxicillin/clavulanate (FEAMC); failure at day 21; and 30 day mortality. Classification and regression tree (CART) analysis and logistic regression were performed.<br />[Results] Overall, 264 episodes were included; the urinary tract was the most common source (64.7%) and Escherichia coli the most frequent pathogen (76.5%). Fifty-two isolates (19.7%) showed resistance according to CLSI and 141 (53.4%) according to EUCAST. The kappa index for the concordance between the results of both committees was only 0.24. EUCAST-derived, but not CLSI-derived, MICs were associated with failure when considered as continuous variables. CART analysis suggested a ‘resistance’ breakpoint of > 8/4 mg/L for CLSI-derived MICs; it predicted FEAMC in adjusted analysis (OR = 1.96; 95% CI: 0.98–3.90). Isolates with EUCAST-derived MICs >16/2 mg/L independently predicted FEAMC (OR = 2.10; 95% CI: 1.05–4.21) and failure at day 21 (OR= 3.01; 95% CI: 0.93–9.67). MICs >32/2 mg/L were only predictive of failure among patients with bacteraemia from urinary or biliary tract sources.<br />[Conclusions] CLSI and EUCAST methodologies showed low agreement for determining the MIC of amoxicillin/clavulanate. EUCAST-derived MICs seemed more predictive of failure than CLSI-derived ones. EUCAST-derived MICs >16/2 mg/L were independently associated with therapeutic failure.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1257733418
Document Type :
Electronic Resource